31 results
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
control over the shares.
4. Registration Expenses. All fees and expenses incident to the performance of or compliance with, this Agreement … the securities.
The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
incident to the performance of or compliance with, this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities … fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
and dispositive control over the shares.
4.Registration Expenses. All fees and expenses incident to the performance of or compliance … by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
21 Nov 22
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million
7:00am
by such party incident to the negotiation, preparation, execution, delivery and performance of this letter agreement. The Company shall pay all transfer
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement, the Purchase Agreement, the Securities
8-K
EX-3.2
m3mbq
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
DRS/A
EX-3.4
3jt813h5j09z3w
8 Jul 14
Draft registration statement (amended)
12:00am
8-K
EX-3.1
zkwkp2hkn63c9pd5
4 Aug 22
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-3.2
y7qycril67o 0p4
20 Feb 15
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
EX-2.1
awe6uxcxsrj496o1kkn
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
EX-10.1
3mgo6 ts7d3c
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
8-K
EX-10.1
6026rcunol1
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
b50wq59btvutn92qk
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-1.1
g8glm26rbmlcu1gjgy
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-10.1
ajo ckejc3vlt
13 Apr 18
EyeGate Announces $11.25 Million Public Offering
12:00am